June 21, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has established operations in Mexico and will commence shipment of its Cannabinol products throughout Mexico within the coming weeks.
With the Monday June 19th, 2017 announcement by Mexican President Enrique Pena Nieto, Mexico has now officially legalized Medical Marijuana. The bill legalizes the buying, selling, importing and exporting of cannabis products with less than 1% THC. Cannabis related products are now available for medical use and gives people in Mexico access to products containing THC for the first time.
CEO of Isodiol International Inc. Marcos Agramont stated, “Anticipating the medical cannabis legalization in Mexico, we have spent the last few months investing in infrastructure to expand our distribution into that market. Through our online sales platform, we will immediately be able to commence distribution and build a footprint within Mexico. We will also continue to work through the approval process with Comision Federal para la Proteccion contra Riesgos Sanitarios (“COFEPRIS”) for our manufacturing permit which will allow us to produce in Mexico. This is a very important step for us, as we continue to build out a fully vertically integrated operation, which is being replicated domestically and in every market we enter.”
The company will provide additional information in the coming weeks.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.